ProfoundBio to Participate in the 21st Annual Morgan Stanley Conference
2023-08-28
ProfoundBio Announces Further Advancement of Lead Programs - PRO1184 (Rinatabart Sesutecan) and PRO1160 in the Clinic
2023-05-26
ProfoundBio Announces Initiation of First-in-Human Trial for PRO1184, a Folate Receptor Alpha-Directed ADC with a Topoisomerase 1 ......
2023-01-03
ProfoundBio Receives FDA "Study May Proceed" Letter for PRO1184 and Welcomes Naomi Hunder MD, as Chief Medical Officer
2022-08-03
ProfoundBio Announces Completion of $70 Million Series A+ Financing
2022-06-02
ProfoundBio to Highlight Programs and Technology at AACR 2022 Annual Meeting and Welcomes Zhu Chen, PhD, as Chief Scientific Offic......
2022-03-09
ProfoundBio Announces Presentation on Novel, Proprietary Linker-Drug Technology to Enable Antibody-Drug Conjugates (ADCs) with an ......
2021-10-08
ProfoundBio Announces Completion of More Than $55 million Series A Financing
2021-07-12
